menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Nhwa Pharmaceutical","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Jiangsu Nhwa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu Nhwa Pharmaceutical

    Menu

    Jiangsu Nhwa Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Nhwa Pharmaceutical

                            China arrow
                            Pharma Live Expo
                            Not Confirmed

                            Jiangsu Nhwa Pharmaceutical

                            China arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deutetrabenazine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Teva and Jiangsu Nhwa Partner to Promote AUSTEDO® Access in China

                            Details : The partnership focuses on commercializing Teva’s Austedo (deutetrabenazine), FDA-approved for treating tardive dyskinesia and chorea associated with Huntington’s disease.

                            Product Name : Austedo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 26, 2024

                            Lead Product(s) : Deutetrabenazine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth